|
Bridgehead's clients include top 5 pharmaceutical companies, leading biotechnology and medical device companies, major banks and investors. We also work with academic groups and SMEs at the forefront of innovation.
"I am happy with the feedback from my Top Management related to the P&R scan. You did a great job." Director, Global Health Outcomes & Market Access, Sanofi Aventis
"Very many thanks for a piece of very thorough and good quality in-depth work." Director Global Pricing & Market Access, AstraZeneca
"The evaluation of product positioning conducted by Bridgehead for Thiakis made a valuable contribution to our corporate strategy" CEO, Thiakis
"Bridgehead helped guide us towards setting achievable and attainable objectives. They provided the strategic input, payer knowledge and contacts, and an experienced moderator to ensure the success of the advisory board meeting." Vice President, Global Marketing, Bristol-Myers Squibb
|
"We were extremely pleased with Bridgehead´s speed and flexibility in meeting our requirements for the commercial analysis of this important strategic transaction." Senior Director, Global Marketing & Medical Affairs, Almirall
"We were extremely satisfied with the support provided by Bridgehead in our efforts to find a partner for one of our promising out-licensing candidates. We were very much impressed by their professional skills during the project valuation process and the identification of the best suitable potential licensees." Head of Clinical Research, Merckle GmbH
“Once again you did an excellent job with this advisory board. We were very happy with both the planning and execution, and it provided us with extremely valuable insights which we will incorporate into our future plans. So well done.” Director, Strategic Pricing & Reimbursement
"We asked Bridgehead to work to a very aggressive timescale and we were very impressed that they met our needs while producing a very comprehensive and professional report. The Bridgehead staff were well informed, very thorough in their assessment and rigorous in their analysis and findings. The timely delivery of their Experts' Report was critical to our successful admission to AIM/IEX and I have no hesitation in recommending them." Chief Executive Officer, AGI Therapeutics
|
